Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Product containing precisely doxorubicin hydrochloride 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 50 mg/100 ml blæreinstillationsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 50 mg/50 ml blæreinstillationsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 2 mg/ml infusionsvæske, opløsning, hætteglas a 150 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 10 mg pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 20 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Doxorubicin hydrochloride 150mg/vial powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 2 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 2 mg/ml injektionsvæske, opløsning, hætteglas a 100 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 2 mg injektionsvæske, opløsning 37,5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 2 mg injektionsvæske, opløsning, hætteglas a 75 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Doxorubicin hydrochloride 100mg/vial powder |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 10 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Doxorubicin hydrochloride 50mg powder for injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Doxorubicin hydrochloride 2mg/mL injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 2 mg injektionsvæske, opløsning, hætteglas a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 50 mg hætteglas pulver |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 2 mg injektionsvæske, opløsning, hætteglas a 25 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 150 mg/75 ml infusionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
doxorubicinhydrochlorid 10 mg/5 ml injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Daunorubicin hydrochloride liposome (substance) |
Is a |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Doxorubicin hydrochloride 10 mg powder for solution for injection vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Daunorubicin hydrochloride liposome (substance) |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Doxorubicin hydrochloride 10 mg powder for solution for injection vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Doxorubicin hydrochloride 10 mg powder for solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 50 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 200 milligram/100 milliliter conventional release solution for injection vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 200 milligram/100 milliliter conventional release solution for injection vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 20 milligram/10 milliliter conventional release solution for infusion vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 20 milligram/10 milliliter conventional release solution for infusion vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 50 milligram/25 milliliter conventional release solution for infusion vial |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 50 milligram/25 milliliter conventional release solution for infusion vial |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Doxorubicin hydrochloride pegylated liposome |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
|
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for infusion (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for infusion (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |
Product containing precisely doxorubicin hydrochloride 2 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Doxorubicin hydrochloride |
Inferred relationship |
Some |
1 |